BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology in pancreatic cancer

 BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology in pancreatic cancer

BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology in pancreatic cancer

Shots:
  • Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study
  •  Results of Ph2a COMBAT study is expected in H2’18 as planned
  • This study is assessing combination of BL-8040 & Keytruda in metastatic 1L+ patients
Click here to read full press release/ article | Ref: Biolinerx | Image: LinkedIn

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post